Skip to Main Content

Paper Details

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.
J Am Heart Assoc
12
2022
HF, Heart Failure, Icosapent Ethyl, Icosapent ethyl, Patients, atherosclerotic cardiovascular disease, cardiovascular death, heart failure, high-sensitivity C-reactive protein, hs-CRP, icosapent ethyl, men, nonfatal myocardial infarction, nonfatal stroke, participants, patients, statin, triglyceride, triglycerides, unstable angina
Author NameAffiliation
Deepak L BhattBrigham and Women's Hospital Heart & Vascular Center Harvard Medical School Boston MA.
Jean-Claude TardifMontreal Heart InstituteUniversite de Montreal Montreal QC Canada.
Christie M BallantyneDepartment of Medicine Baylor College of MedicineCenter for Cardiovascular Disease PreventionMethodist DeBakey Heart and Vascular Center Houston TX.
Christie M BallantyneDepartment of Medicine Baylor College of MedicineCenter for Cardiovascular Disease PreventionMethodist DeBakey Heart and Vascular Center Houston TX.
  • 1 - 4

Datasets

Release 1.2